Status:
COMPLETED
Viviant 20mg Special Investigation (Regulatory Post Marketing Commitment Plan)
Lead Sponsor:
Pfizer
Conditions:
Osteoporosis
Eligibility:
FEMALE
Brief Summary
In this survey, to collect the safety and efficacy information of Bazedoxifene in daily medical practice will be examined. In addition, the necessity of special Investigation and post-marketing clinic...
Detailed Description
All the subjects whom an investigator prescribes the first Bazedoxifene (Viviant) Tablets should be registered consecutively until the number of subjects reaches target number in order to extract pati...
Eligibility Criteria
Inclusion
- Post menopausal women subjects with Osteoporosis who has no experience of use of Bazedoxifene.
Exclusion
- Subject with present or past venous thromboembolism such as deep venous thrombosis, pulmonary embolism, or retinal venous thrombosis
- Subject in long-term immovability (postoperative recovery, long-term bed rest)
- Subject with antiphospholipid antibody syndrome
Key Trial Info
Start Date :
November 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2016
Estimated Enrollment :
3187 Patients enrolled
Trial Details
Trial ID
NCT01470326
Start Date
November 1 2011
End Date
June 1 2016
Last Update
November 5 2018
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.